Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors for 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million before expenses, with the offering closing on August 15, 2025.
Maxim Group LLC is the sole placement agent for the offering, conducted under an effective shelf registration statement on Form S-3.
Offering Details
3,225,000 shares of common stock at $1.20 per share with gross proceeds around $3.9 million.
Placement Agent
Maxim Group LLC is the sole placement agent for the offering.
Registration Statement
The offering is made under an effective shelf registration statement on Form S-3 (File No. 333-289198).
Prospectus Information
The shares will be offered through a prospectus supplement available on the SEC's website.
- The offering provides Scienture Holdings, Inc. with additional capital to support its pharmaceutical operations.
- Maxim Group LLC's involvement as the placement agent adds credibility to the offering process.
The Registered Direct Offering enhances Scienture Holdings, Inc.'s financial position and supports its focus on developing novel specialty products for unmet market needs.